Expression of METTL7B in Newly Diagnosed Patients with Acute Myeloid Leukemia and Its Influence on Prognosis.
10.19746/j.cnki.issn.1009-2137.2025.05.008
- Author:
Wen-Bang ZHANG
1
;
Shu-Xia GUO
1
;
Xiao-Juan ZHANG
1
;
Huan-Jun LIU
1
;
Meng-Yao LIU
1
Author Information
1. The Fifth Clinical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital); Department of Hematology, People's Hospital of Henan University of Chinese Medicine, Zhengzhou 455003, Henan Province, China.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia
- MeSH:
Humans;
Leukemia, Myeloid, Acute/metabolism*;
Prognosis;
Methyltransferases/metabolism*;
Male;
Female;
Middle Aged;
Adult;
Proportional Hazards Models
- From:
Journal of Experimental Hematology
2025;33(5):1287-1292
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To detect the expression of methyltransferase-like 7B ( METTL7B) in bone marrow specimens of patients with acute myeloid leukemia (AML), and to analyze its influence and significance on clinical diagnosis, treatment, and prognosis of AML patients.
METHODS:Bone marrow specimens from 60 newly diagnosed AML patients were collected as the observation group, and bone marrow specimens from 20 iron-deficiency anemia (IDA) patients were collected as the control group. Clinical and pathological data of AML patients were also collected. Real-time fluorescent quantitative PCR (qRT-PCR) was used to detect the expression of METTL7B in AML patients and IDA patients. Statistical analyses were performed to investigate the relationship between the expression level of METTL7B and clinical-pathological characteristics in AML patients, as well as the impact of METTL7B expression level on efficacy. Kaplan-Meier method was used to analyze the effect of METTL7B expression level on the overall survival time (OS) in AML patients. Meanwhile, a Cox proportional hazards regression model was constructed to identify the factors potentially affecting the prognosis of AML patients.
RESULTS:Compared with the control group, the expression level of METTL7B was significantly upregulated in AML patients (P < 0.05). Compared with the low-expression group of METTL7B, the high-expression group had a higher proportion of patients with high white blood cell (WBC) count, poor prognosis, and ineffective treatment, and the differences were statistically significant (P < 0.05). The OS of patients in the high-expression group of METTL7B was significantly shorter than that in the low-expression group (P < 0.05). Multivariate Cox regression analysis showed that high WBC count, poor prognosis in prognosis stratification, and high expression of METTL7B were independent risk factors for the prognosis of AML patients (P < 0.05).
CONCLUSION:METTL7B is highly expressed in AML patients, and patients with high METTL7B expression exhibit shorter survival and poor prognosis. METTL7B is expected to serve as a new indicator for evaluating the prognosis of AML patients and may develop into a potential target for targeted treatment of AML in the future.
